Therapeutic Advances in Cardiovascular Disease

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Romayne Kurukulasuriya, L.
Right arrow Articles by Sowers, J. R.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Therapeutic Advances in Cardiovascular Disease, Vol. 1, No. 1, 49-59 (2007)
DOI: 10.1177/1753944707082714

Reviews

Review: HMG CoA reductase inhibitors and renoprotection: the weight of the evidence

L. Romayne Kurukulasuriya

Adam Whaley Connell University of Missouri-Columbia School of Medicine, Diabetes Center, D109 HSC, One Hospital Dr, Columbia, MO 65212

Ganesh Athappan

Adam Whaley Connell University of Missouri-Columbia School of Medicine, Diabetes Center, D109 HSC, One Hospital Dr, Columbia, MO 65212

Georges Saab

Adam Whaley Connell University of Missouri-Columbia School of Medicine, Diabetes Center, D109 HSC, One Hospital Dr, Columbia, MO 65212

Adam Whaley Connell

Adam Whaley Connell University of Missouri-Columbia School of Medicine, Diabetes Center, D109 HSC, One Hospital Dr, Columbia, MO 65212, whaleyconnella@health. missouri.edu

James R. Sowers

Adam Whaley Connell University of Missouri-Columbia School of Medicine, Diabetes Center, D109 HSC, One Hospital Dr, Columbia, MO 65212

Dyslipidemia and the contributions of oxidized low-density lipoproteins (ox-LDL) are independent cardiovascular risk factors. There is growing evidence that dyslipidemia contributes not only to cardiovascular disease but also to the progressive decline of renal function in diabetic and non-diabetic kidney disease. Ox-LDL, by generating inflammation and oxidative stress, contributes to a pro-atherogenic mileu and leads to endothelial dysfunction, subsequent glomerular filtration barrier damage, and progressive renal injury. Chronic kidney disease (CKD), in turn, induces deleterious effects on lipid metabolism. Therefore, by inhibiting cholesterol synthesis and reducing ox-LDL, HMG CoA reductase inhibitors (statins) are attractive therapeutic options to preserve renal function. Current evidence demonstrates a reduction in cardiovascular risk and improved renal outcomes especially in patients with mild to moderate impairment of renal function. Evidence supports a beneficial role of statins thought to extend beyond their lipid-lowering effect, referred to as pleiotropic actions. These actions include modulatory effects on inflammation, oxidative stress and thrombosis, derived from their ability to prevent the formation of isoprenoid intermediates involved in cellular signaling, posttranslational modification of proteins and cellular function. This translates to potential reductions in the rate of decline in GFR in CKD and adverse effects of type 2 diabetes mellitus in the kidney. This review examines the role of statins for reno-protection as well as cardiovascular benefit in patients with CKD.

Key Words: HMG-CoA reductase inhibitor • chronic kidney disease • inflammation • oxidative stress.

References

  • Agarwal, R. (2004) Statin induced proteinuria: renal injury or renoprotection? J Am Soc Nephrol 15: 2502—2503.[Free Full Text]
  • Antonio, C. (2006) Controlling oxidative stress as a novel molecular approach to protecting the vascular wall in diabetes. Curr Opin Lipidol 17: 510—518.[Medline] [Order article via Infotrieve]
  • Arthyros, V.G. et al. (2004) The effects of statins versus untreated syslipidemia on renal function in patients with coronary artery disease. A subgroup analysis of the Greek atovastatin and coronary artery disease evaluation (GREACE) study. J Clin Pathol 57: 728—734.[Abstract/Free Full Text]
  • Attman, P.O. et al. (1999) Apo lipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 55(4): 1536—1542.[CrossRef][Medline] [Order article via Infotrieve]
  • Baigent C. and Landry M. (2003) Study of Heart and Renal Protection (SHARP). [Review] Kidney Int. — Supplement (84): S207—210.[Medline] [Order article via Infotrieve]
  • Baigent, C. et al. (2000) Premature cardiovascular disease in chronic renal failure. Lancet 356: 147—152.[CrossRef][Medline] [Order article via Infotrieve]
  • Bianchi, S. et al. (2003) A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41: 565—570.[CrossRef][Medline] [Order article via Infotrieve]
  • Boes, E. et al. (2006) Apo lipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 17: 528—536.[Abstract/Free Full Text]
  • Bussolati, B. et al. (2005) Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/ AKT-signaling pathway. J Am Soc Nephrol 16: 1936—1947.[Abstract/Free Full Text]
  • Campese, V.M. et al. (2005) Are 3 hydroxy3-methylglutaryl CoA reductase inhibitors renoprotective? J Am Soc Nephrol 16: S11—S17.[Abstract/Free Full Text]
  • Cases, A. and Colli, E. (2005) Colli E Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl 68: S87—S93.
  • Chen, H.C. et al. (2002) Pravastatin suppress super oxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose. Atherosclerosis 160: 141—146.[CrossRef][Medline] [Order article via Infotrieve]
  • Chmielewski, M. et al. (2005) Expression of scavenger receptor CD36 in chronic renal failure patients Artificial Organs 29: 608—614.[CrossRef][Medline] [Order article via Infotrieve]
  • Deighan, C.J. et al. (2000) Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis 35: 852—862.[Medline] [Order article via Infotrieve]
  • Dichtl, W. et al. (2003) HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 23: 58—63.[Abstract/Free Full Text]
  • Dusi, S. et al. (1995) Mechanism of NADPH oxidase activation in human neutrophils: p67phox is required for translocation of rac1 but not rac2 from cytosol to the membranes. Biochem J 308: 991—994.[Medline] [Order article via Infotrieve]
  • Epstein, M. and Campese, V.M. (2005) Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis 45: 2—14.[Medline] [Order article via Infotrieve]
  • Fellstrom, B.C. et al. (2003) Holdaas H. Jardine AG. Why do we need a statin trial in hemodialysis patients Kidney Int. — Supplement (84): S204—6.
  • Foley, R.N. et al. (1995) Clinical and echocardiographic disease in patients starting end stage renal disease therapy. Kidney Int 47: 186—92.[Medline] [Order article via Infotrieve]
  • Fried, L.F. et al. (2001) for the Lipids and Renal Disease Progression Meta-Analysis Study Group Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 59: 260—269.[CrossRef][Medline] [Order article via Infotrieve]
  • Grandaliano, G. et al. (1993) Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int 44: 503—508.[Medline] [Order article via Infotrieve]
  • Grassmann, A. et al. (2006) End-stage renal disease: global demographics in 2005 and observed trends. Artif Organs 30: 895—897.[CrossRef][Medline] [Order article via Infotrieve]
  • Griffin, B.A. et al. (1994) Role of plasma triglyceride in the regulation of plasma low-density lipoprotein (LDL) subfractions: Relative contribution of small, dense LDL to coronary heart disease. Atherosclerosis 106: 241—253.[CrossRef][Medline] [Order article via Infotrieve]
  • Guijarro, C. and Egido, J. (2001) Transcription factor-kappaB (NF kappaB) and renal disease. Kidney Int 59: 415—424.[CrossRef][Medline] [Order article via Infotrieve]
  • Habibi, J. et al. (2007) Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Endocrinology 148: 2181—2188.[Abstract/Free Full Text]
  • Ikewaki, K. et al. (2005) Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis. Arterioscler Thromb Vasc Biol 25: 2615—2622.[Abstract/Free Full Text]
  • Kasiske, B.L. et al. (2006) An assessment of statin safety by nephrologists. Am J Cardiol 97: S82—S85.[CrossRef]
  • Kim, S.Y. et al. (1995) Human mesangial cell production of monocyte chemo attractant protein-1: modulation by lovastatin. Kidney Int 48: 363—371.[Medline] [Order article via Infotrieve]
  • Kronenberg, F. et al. (2004) The Apolipoprotein (a) size polymorphism is associated with nephrotic syndrome. Kidney Int 65: 606—612.[CrossRef][Medline] [Order article via Infotrieve]
  • Kronenberg, F. et al. (2000) Lipoprotein(a) serum concentrations and Apo lipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 11: 105—115.[Abstract/Free Full Text]
  • Kronenberg, F. et al. (2002) Apolipoprotein A-IV serum concentrations are elevated in mild and moderate renal failure. J Am Soc Nephrol 13: 461—469.[Abstract/Free Full Text]
  • Kuldo, J.M. et al. (2005) Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases. Curr Vasc Pharmacol 3: 11—39.[CrossRef][Medline] [Order article via Infotrieve]
  • Lee, D.M. et al. (2002) Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency. Kidney Int 61: 209—218.[CrossRef][Medline] [Order article via Infotrieve]
  • Lee, T.M. et al. (2002) Effect of pravastatin on proteinuria in patients with well-controlled hypertension. Hypertension 40: 67—73.[Abstract/Free Full Text]
  • Mason, P.R. et al. (2004) Effects of HMG- CoA reductase inhibitors on endothelial function. Circulation 109: II-34—II-41.[Medline] [Order article via Infotrieve]
  • Massy, Z.A. et al. (2000) Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin. Biochem Biophys Res Commun 267: 536—540.[CrossRef][Medline] [Order article via Infotrieve]
  • McFarlane, S.I. et al. (2002) Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 87: 1451—1458.[Abstract/Free Full Text]
  • Moorhead, J.F. et al. (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2: 1309—1312.[Medline] [Order article via Infotrieve]
  • Moorhead, J.F. et al. (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2: 1309—1311.[Medline] [Order article via Infotrieve]
  • Muntner, P. et al. (2000) Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 58: 293—301.[CrossRef][Medline] [Order article via Infotrieve]
  • Oda, H. and Keane, W.G. (1999) Recent advances in statins and the kidney. Kidney Int Suppl 71: S2—S5.[Medline] [Order article via Infotrieve]
  • Ozsoy, R.C. et al. (2006) The dyslipidemia of chronic renal disease: effects of statin therapy. Curr Opin Lipidol 17: 659—666.[Medline] [Order article via Infotrieve]
  • Ozsoy, R.C. et al. (2006) The dyslipidemia of chronic renal disease: effects of statin therapy. Curr Opin Lipidol 17: 659—666.[Medline] [Order article via Infotrieve]
  • Rovin, B.H. and Tan, L.C. (1993) LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 43: 218—225.[Medline] [Order article via Infotrieve]
  • Samuelsson, O. et al. (1998) Complex Apo lipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol 9: 1482—1488.[Abstract]
  • Samuelsson, O. et al. (1997) Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 12: 1908—1915.[Abstract/Free Full Text]
  • Sandhu, S. et al. (2006) Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17: 2006—2016.[Abstract/Free Full Text]
  • Sarnak, M.J. et al. (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 108: 2154—2169.[Free Full Text]
  • Schaeffner, E.S. et al. (2003) Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 14: 2084—2091.[Abstract/Free Full Text]
  • Schaeffner, E.S. et al. (2003) Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 14: 2084—2091.[Abstract/Free Full Text]
  • Seliger, S.L. et al. (2002) HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61: 297—304.[CrossRef][Medline] [Order article via Infotrieve]
  • Thysell, H. et al. (1995) Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. Kidney Int 48: 779—784.[Medline] [Order article via Infotrieve]
  • Tonelli, M. et al. (2003) Effect of Pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14: 1605—1613.[Abstract/Free Full Text]
  • Tonelli, M. et al. (2005) Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112: 171—178.[Abstract/Free Full Text]
  • Utermann, G. et al. (1987) Lp (a) glycoprotein phenotypes: inheritance and relation to Lp (a)-lipoprotein concentrations in plasma. J Clin Invest 80: 458—465.[Medline] [Order article via Infotrieve]
  • Vamvakopoulos, J.E. and Green, C. (2003) HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: a potential mechanism of statin-mediated vasculoprotection. BMC Cardiovasc Disord 3: 6.[CrossRef][Medline] [Order article via Infotrieve]
  • Vaziri, N.D. (2006) Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am Journal of Physiol — Renal Physiol 290: F262—F272.
  • Vidt, D.G. (2005) Statins and proteinuria. Curr Atheroscler Rep 7: 351—357.[Medline] [Order article via Infotrieve]
  • Vidt, D.G. et al. (2004) Rosuvastatin-induced arrest in progression of renal disease. Cardiology 102: 52—60.[CrossRef][Medline] [Order article via Infotrieve]
  • Wanner, C. et al. (2005) German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. New Engl J Med 353: 238—248.[Abstract/Free Full Text]
  • Whaley-Connell, A.T. et al. (2007) Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells. Am J Nephrol 27: 15—23.[CrossRef][Medline] [Order article via Infotrieve]
  • Wolfrum, S. et al. (2003) Endothelium dependent effects of statins. Arterioscler Thromb Vasc Biol 23: 729—736.[Abstract/Free Full Text]
  • Zelvyte, I. et al. (2002) Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 45: 147—154.[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Romayne Kurukulasuriya, L.
Right arrow Articles by Sowers, J. R.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?